"I've been running R&D, and I think the CEO should be the chief product officer, so I'm making no changes to our R&D leadership team; it will continue to report directly to me," he said in an interview on Wednesday.
Levin declined to provide more information about Gronager other than to say that Gronager is also no longer on the Chainalysis board but retains his equity in the company.
Chainalysis' financial health appears strong, with Levin stating they don't need to raise capital after last year's $175 million funding, focusing on growth and client support.
Chainalysis, whose early investors include Benchmark, was valued by investors at $8.6 billion during that 2022 funding round.
Collection
[
|
...
]